West Pharmaceutical Services, Inc. WST
- Market cap
- $26.3B
- P/E
- 47.1×
Follow WST
West Pharmaceutical Services, Inc. (WST) P/B ratio
As of 25 September 2026, West Pharmaceutical Services, Inc. (WST) trades at a P/B ratio of 8.8×. Over the past ten years it has ranged from 3.6× (February 2015) to 17.1× (September 2021); the current reading is higher than 67% of that period. That is above the Medical Instruments & Supplies industry median of 2.8× and above the Healthcare sector median of 2.5×.
P/B ratio, daily
Annual
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 6.3× | (29.74%) |
| FY2024 | 8.9× | (0.87%) |
| FY2023 | 9.0× | 38.44% |
| FY2022 | 6.5× | (56.53%) |
| FY2021 | 14.9× | 32.35% |
| FY2020 | 11.3× | 59.66% |
| FY2019 | 7.1× | 36.29% |
| FY2018 | 5.2× | (9.69%) |
| FY2017 | 5.7× | 4.18% |
| FY2016 | 5.5× | 30.22% |
Quarterly
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 8.5× | 40.86% |
| Mar 2026 | 6.0× | (3.65%) |
| Dec 2025 | 6.3× | 0.91% |
| Sep 2025 | 6.2× | 15.09% |
| 42 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| COO The Cooper Companies, Inc. compare | 1.3× |
| ALC Alcon compare | 1.5× |
| MDLN Medline Inc. compare | 1.6× |
| BAX Baxter International Inc. compare | 2.0× |
| BDX Becton, Dickinson and Company compare | 2.1× |
| SOLV Solventum Corporation compare | 3.2× |
| RMD ResMed Inc. compare | 4.9× |
| RGEN Repligen Corporation compare | 5.1× |
| WST West Pharmaceutical Services, Inc. | 8.8× |
| Medical Instruments & Supplies industry median | 2.8× |
| Healthcare sector median | 2.5× |
| Market median | 1.8× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on WST
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement